Your session is about to expire
← Back to Search
Linperlisib for Peripheral T-Cell Lymphoma
Study Summary
This trialwill test a drug to treat a type of cancer in adults in the US. It will measure safety, efficacy & how it's absorbed.
- Peripheral T-Cell Lymphoma (Relapsed/Refractory)
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You regularly use illegal or recreational drugs, or you have had issues with drug or alcohol abuse within the past year.You have had another type of cancer in the last five years or still have signs of cancer from a previous diagnosis.You have had an allergic reaction to linperlisib or any of its ingredients before.You have a type of lymphoma called angioimmunoblastic T-cell lymphoma (AITL).You are not eligible for a self-donated or donated transplant.You are willing to give a sample of your tumor tissue that was previously collected or undergo a new biopsy before treatment.You have already received treatment for your condition but it did not work.You have multiple conditions that can affect how the drug is taken up and absorbed by your body.You have experienced inflammation of the colon or lungs caused by medication in the past.You had a bleeding episode within the last 2 months, or your doctor thinks you may experience bleeding easily.You have natural-killer/T-cell lymphoma (NKTCL).You have a type of lymphoma called CD30+ PTCL, and have either not responded well to or cannot tolerate the medication brentuximab vedotin.You are 18 years old or older and have agreed to participate in the study.You have a type of lymphoma called peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).You have a type of lymphoma called anaplastic large cell lymphoma (ALCL), regardless of whether it is ALK positive or ALK negative.You have a specific type of cancer called Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (MEITL).
- Group 1: YY-20394
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the magnitude of participants in this experiment?
"Affirmative. According to clinicaltrials.gov, this medical research project is actively recruiting individuals since its original posting date of May 1st 2022 and most recent update on October 19th 2022. The study needs 97 participants from one location in total."
Are there any opportunities for volunteers to join this research project at present?
"According to clinicaltrials.gov, the recruitment process for this trial is still ongoing - it was first posted on May 1st 2022 and revised lastly on October 19th 2022."
Has the drug YY-20394 attained regulatory approval from the Food and Drug Administration?
"YY-20394's safety rating is 2, as there are reports testifying to its security but a dearth of evidence regarding it efficacy."
Share this study with friends
Copy Link
Messenger